Datamonitor's October
edition of the Infectious Diseases Review brings you the latest news,
expert analysis and research in the infectious diseases market.
It covers all the major current business
issues and events, including R&D, licensing deals, alliances and joint
ventures, and regulatory decisions.
Scope
-
Strategic insight into the future shape
of infectious diseases companies and markets
-
The most significant infectious
diseases news compiled into one monthly update
-
Expert analysis into the implications
of the month's important events in infectious diseases
-
Insight into the future shape of the
market for players at all levels
-
All the month's infectious diseases
stories in headline and summary form
Report Highlights
Out of the dozens of topics covered in this
month's review, the most important include:
* The Immune Response Corporation released
results from an ongoing Canadian study, which gave the first indication in
clinical trials that Remune might give relief for HIV-infected patients
from the adverse side-effects of antiretroviral therapies.
* GlaxoSmithKline launched a lawsuit
against a Novartis subsidiary that manufactures a generic version of its
antibiotic Augmentin. GlaxoSmithKline claims the generic version is based
on a type of bacteria stolen by a former employee.
Reasons to Purchase
-
Not only keeps you updated about
industry events - it also gives you opinion and insight
-
Draws upon Datamonitor analysts'
extensive experience to bring you our perspective on the impact of the
latest events
-
Provides you with your own news archive
to track company and industry progress, giving you an extensive
reference to relevant events and issues
R&D UPDATE: HIV
The most significant news
in HIV R&D, compiled into one monthly update.
R&D UPDATE: HEPATITIS
The most significant news
in hepatitis R&D, compiled into one monthly update.
R&D UPDATE: BACTERIAL INFECTIONS
The most significant news
in bacterial infections R&D, compiled into one monthly update.
R&D UPDATE: FUNGAL INFECTIONS
The most significant news
in fungal infections R&D, compiled into one monthly update.
R&D UPDATE: OTHER INFECTIOUS
The most significant news
in other infectious R&D, compiled into one monthly update including:
LATEST COMMENT
Expert analysis of the
implications of the month's important industry events
-
Cipla: lobbying for more generics in
South Africa
-
Alternative therapies: hurting HIV
regimes
-
HIV treatment: non-compliance brings
pitfalls without benefits
-
Lilly: no European rebirth for Xigris
-
Bayer: seeking Gamunex approval
FEATURE ANALYSIS
Analyst-written feature
articles, featuring the latest insights into the industry
-
HIV: the crisis continues
NEWS HEADLINES - HIV
All the month's HIV news
stories in headline and summary form
NEWS HEADLINES - HEPATITIS
All the month's hepatitis
news stories in headline and summary form
NEWS HEADLINES - BACTERIAL INFECTIONS
All the month's bacterial
infections news stories in headline and summary form
NEWS HEADLINES - FUNGAL INFECTIONS
All the month's fungal
infections news stories in headline and summary form
NEWS HEADLINES - OTHER INFECTIOUS
All the month's other
infectious news stories in headline and summary form.
To
order - click here!
